Document:

EX-10.7

 Exhibit 10.7 

GU Reference: 2016-058 

EXCLUSIVE LICENSE AGREEMENT 

BETWEEN 
 GEORGETOWN
UNIVERSITY 
 AND 

X4 PHARMACEUTICALS, INC. 

This Exclusive License Agreement (hereinafter “Agreement”) is entered into and effective as of the 13th day of December, 2016
(hereinafter “Effective Date”), by and between GEORGETOWN UNIVERSITY, a Congressionally-chartered academic institution of higher education organized under the laws of the District of Columbia, having its principal place of business located
at 37th and O Streets, N.W., Washington, D.C. 20057 (hereinafter “GEORGETOWN” or “LICENSOR”), and X4 Pharmaceuticals, Inc., a corporation organized under the laws of the state
of Delaware with offices located at 784 Memorial Drive, Suite 140, Cambridge, MA 02139 (hereinafter “LICENSEE”). 
 WHEREAS,
GEORGETOWN AND LICENSEE are joint owners of certain Licensed Patents (as later defined herein) relating to Methods for Treating Cancer; 

WHEREAS, Dr. Michael Atkins of GEORGETOWN is a co-inventor of the Licensed Patents; 

WHEREAS, GEORGETOWN desires to have the Licensed Patents developed and commercialized to benefit the public and is willing to grant a license
to LICENSEE hereunder; 
 WHEREAS, LICENSEE has represented to GEORGETOWN, to induce it to enter into this Agreement, that LICENSEE shall
commit itself to a diligent program of exploiting the Licensed Patents so that public utilization shall result therefrom; and 
 WHEREAS,
LICENSEE desires to obtain an exclusive license to GEORGETOWN’s joint ownership rights under the Licensed Patents upon the terms and conditions hereinafter set forth. 

NOW, THEREFORE, the Parties agree as follows: 

ARTICLE 1 
 Definitions

  

	1.1	 Terms in this Agreement (other than names of parties and Article headings) that are set forth with a
capitalized first letter have the meanings established for such 

  
 1 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 

	 	terms in this Article 1 unless otherwise expressly defined in this Agreement (such definitions shall be equally applicable to both the singular and plural forms of the defined terms). The words “hereof,”
“herein” and “hereunder” and words of like import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and Section references are to this Agreement unless
otherwise specified. 

  

	1.2	 “Affiliate” shall mean any corporation or other entity that directly or indirectly controls, is
controlled by or is under common control with a Party to this Agreement. A corporation or other entity shall be regarded as in control of another corporation or entity if it owns or directly or indirectly controls more than fifty percent (50%) of
the voting stock or other ownership interest of the other corporation or entity, or if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or other entity or the power to
elect or appoint fifty percent (50%) or more of the members of the governing body of the corporation or other entity. 

  

	1.3	 “Commercially Reasonable Efforts” shall mean, [***]. 

 

	1.4	 “Effective Date” shall mean the date first written above. 

 

	1.5	 “End User” shall mean a Person who acquires a Licensed Product directly or indirectly from Licensee,
for use and not for resale following First Commercial Sale. 

  

	1.6	 “Field” means all therapeutic, prophylactic and diagnostic uses in all disease indications in humans
and animals. 

  

	1.7	 “First Commercial Sale” means the initial transfer by or on behalf of LICENSEE or its Sublicensees of
Licensed Products to a Third Party in exchange for cash or some equivalent to which value can be assigned for the purpose of determining Net Sales. For avoidance of doubt, First Commercial Sale excludes transfers or dispositions of a Licensed
Product between LICENSEE and its Affiliates and Sublicensees or for charitable, promotional (including samples), pre-clinical, clinical or regulatory purposes. 

 

	1.8	 “Licensed Method” means any method that is covered in whole or in part by a Valid Claim contained in
the Licensed Patents. 

  

	1.9	 “Licensed Patents” means [***]. 

 

	1.10	 “Licensed Product” means any product that (a) either is covered by a Valid Claim in the Licensed
Patents, or whose manufacture, use, import, offer for Sale or Sale would constitute, but for the license granted to the LICENSEE pursuant to this 

  
 2 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 

	 	Agreement and LICENSEE’s joint ownership of the Licensed Patents, an infringement of any Valid Claim within the Licensed Patents, or (b) is developed, made, Sold, registered or practiced using the Licensed
Methods or which is authorized to be used to practice the Licensed Methods, in whole or in part. 

  

	1.11	 “Net Sales” means the gross amount invoiced by LICENSEE and its Sublicensees billings to unrelated
Third Parties for the Sale of Licensed Products, less the sum of the following items, to the extent included in the gross amounts invoiced for such Licensed Products or otherwise directly paid, incurred, allowed, accrued or specifically allocated by
LICENSEE or its Sublicensees with respect to the Sale of such Licensed Products: 

  

	 	(a)	 discounts given and actually taken in amounts customary in the trade for quantity/volume purchases, cash
payments, prompt payments, wholesalers and distributors; 

  

	 	(b)	 rebates and chargebacks allowed, given or accrued (including cash, governmental and managed care rebates,
hospital or other buying group chargebacks, cash and non-cash coupons, and governmental taxes in the nature of a rebate based on usage levels or Sales of such Licensed Products); 

 

	 	(c)	 sales, value added, import, export, excise and other taxes directly imposed and with reference to particular
Sales; 

  

	 	(d)	 outbound transportation, customs charges, and insurance charges prepaid or allowed; and 

 

	 	(e)	 amounts allowed or credited on returns or rejections. 

No other deductions shall be made for commissions paid to individuals whether they are with independent sales agencies or regularly employed by
Licensee and on its payroll, or for the cost of collections. Licensed Products shall be considered “sold” [***] after billing or invoicing, or upon receipt of payment, whichever comes first, provided, however, that Licensed Products are
actually shipped to unrelated Third Party customers. If a Licensed Product is distributed or invoiced for a discounted price substantially lower than customary in the trade, Net Sales shall be based on the customary amount billed for such Licensed
Products. Without limiting the generality of the foregoing, transfers or dispositions of a Licensed Product for charitable, promotional (including samples), pre-clinical, clinical, or regulatory purposes will
be excluded from Net Sales. 
  

	1.12	 “Party” means each of LICENSOR and LICENSEE, and “Parties” means both LICENSOR and
LICENSEE. 

  
 3 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
  

	1.13	 “Person” means any legal person or entity, including without limitation any individual, corporation,
partnership, joint venture, association, joint stock company, trust, unincorporated association, limited liability corporation, governmental entity, or other person or entity of similar nature. 

 

	1.14	 To “Sell” a product means to sell, transfer, lease or otherwise dispose of or commercialize a
product. “Sale” and “Sold” have the corollary meanings ascribed thereto. 

  

	1.15	 “Sublicense” means present, future, or contingent transfer of any license, right, option, first right
to negotiate or other right granted under the Licensed Patents, in whole or in part. “Sublicense” includes, without limitation, strategic partnerships, marketing collaborations, and distribution agreements. 

 

	1.16	 “Sublicensee” means any Third Party to whom LICENSEE has granted a license to make, have made, use
and/or Sell the Licensed Product or practice the Licensed Method under the Licensed Patents, provided said Third Party has agreed in writing with LICENSEE to accept any applicable conditions and restrictions agreed to by LICENSEE in this Agreement.

  

	1.17	 “Territory” means worldwide. 

 

	1.18	 “Third Party” means any Person other than the Parties and their respective Affiliates.

  

	1.19	 “Valid Claim” means either: 

 

	 	(a)	 a claim of an issued and unexpired patent that has not been held permanently revoked, unenforceable or invalid
by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise;
or 

  

	 	(b)	 a claim of a pending patent application that was filed in good faith and has not been abandoned or finally
disallowed without the possibility of appeal or refiling of said application. 

 ARTICLE 2 

Grant 
  

	2.1	 Subject to the terms and conditions herein, LICENSOR hereby grants to LICENSEE, in the Field and Territory, an
exclusive license under LICENSOR’s interest in the Licensed Patents to practice the Licensed Methods and to make, have made, use, offer to Sell, Sell and import Licensed Products during the Term. The license includes the right, but not the
obligation, to grant one or more Sublicenses in accordance with the terms of Article 3. 

  
 4 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 

	2.2	 LICENSEE acknowledges and agrees that no license is granted or implied under the Licensed Patent outside the
Field and Territory and will not practice under the Licensed Patent outside the Field and Territory. 

  

	2.3	 This Agreement confers no license, ownership interest in or other rights by implication, estoppel or otherwise
upon LICENSEE in any technology, know how, patents, pending patent applications, or products of LICENSOR except as explicitly set forth in this Agreement, regardless of whether such technology or patent rights shall be dominant or subordinate to any
Licensed Patents. 

 ARTICLE 3 

Sublicensing 
  

	3.1	 LICENSEE shall assure itself of the integrity and financial responsibility of each Person to whom a Sublicense
is granted. 

  

	3.2	 Each Sublicensee shall agree to be bound by all of the obligations, terms and conditions that obligate, bind or
affect LICENSEE under this License Agreement to the extent that such obligations, terms and conditions are relevant given the nature of the rights granted by LICENSEE to any given Sublicensee. 

 

	3.3	 LICENSEE shall be and remain responsible for the performance by each Sublicensee of all of such
Sublicensee’s obligations provided herein. 

  

	3.4	 LICENSEE shall agree to ascertain, compute and audit and shall faithfully ascertain, compute and audit all Net
Sales by each Sublicensee hereunder. 

  

	3.5	 LICENSEE shall not grant any rights under the Licensed Patents to Sublicensee that are inconsistent with this
Agreement or that would be a breach of this Agreement if performed by a Sublicensee. 

  

	3.6	 LICENSEE shall contractually require that each Sublicensee (excluding Third Party Contractors) shall not at any
time, directly or indirectly, in any legal or administrative proceeding oppose the grant of, dispute the validity of, or cooperate in any suit against any patent or claim included in the Licensed Patents (except as required under a court order or
subpoena). 

  

	3.7	 Within [***] after entering into any Sublicense (excluding Sublicenses granted to Third Parties that are
clinical research organizations, contract manufacturers, contract laboratory organizations, and other similar Third Parties that support the development and commercialization of Licensed Products on a fee-for-service basis (“Third Party Contractors”) or any amendment to any such Sublicense, LICENSEE shall notify LICENSOR of the identity of the Sublicensee and shall provide to LICENSOR a copy of
the Sublicense or amendment, which copy may be redacted to omit proprietary and other sensitive information to the extent that such redaction does not impact LICENSOR’s ability to confirm LICENSEE’s compliance with this Agreement.

  
 5 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
  

	3.8	 LICENSEE shall provide to LICENSOR notice of any termination of the Sublicenses described in Section 3.7
within [***] after such event. 

  

	3.9	 Any Sublicense entered into by LICENSEE in violation of the requirements of this Article 3 shall be null and
void and without effect. 

 ARTICLE 4 

Reservation of Rights 
  

	4.1	 LICENSOR expressly reserves all rights not granted herein. LICENSOR reserves all right to disseminate and
publish scientific findings from research conducted by LICENSOR on its own behalf (and not, for clarity, on behalf of LICENSEE) related to the Licensed Patents and Licensed Method, subject to Article 12. LICENSEE reserves all right to disseminate
and publish scientific findings from research conducted by or on behalf of LICENSEE related to the Licensed Patents and Licensed Method. 

ARTICLE 5 
 Licensee
Diligence Obligations 
  

	5.1	 LICENSEE shall use Commercially Reasonable Efforts, or shall cause its Sublicensees to use Commercially
Reasonable Efforts, to develop Licensed Product and to introduce Licensed Product into the commercial market; thereafter, LICENSEE or its Sublicensees shall use Commercially Reasonable Efforts to make Licensed Product reasonably available to the
public. 

  

	5.2	 LICENSEE shall use its Commercially Reasonable Efforts to obtain required government regulatory approval to
manufacture, market and Sell the Licensed Product in the Field in those countries of the Territory where it is commercially reasonable, in LICENSEE’s judgment, to seek such approvals, and shall use its Commercially Reasonable Efforts to market
the Licensed Product in quantities sufficient to meet the market demands for such Licensed Product. 

  
 6 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
 ARTICLE 6 

License Issue Fee and Milestone Payments 
  

	6.1	 License Issue Fee. LICENSEE shall pay to LICENSOR within [***] of the Effective Date of this Agreement,
a license issue fee of fifty thousand dollars ($50,000). The payment is nonrefundable and is not creditable against any other fee or payment. 

  

	6.2	 Milestone Payments. In addition to the License Issue Fee, LICENSEE shall, upon the achievement of the
events set forth below, make the following payments to LICENSOR for each Licensed Product Sold by LICENSEE, its Affiliates and its Sublicensees: 

  

	 	(a)	 [***] dollars ($[***]) upon First Commercial Sale of a Licensed Product. 

 

	 	(b)	 [***] dollars ($[***]) upon achieving the first [***] dollars ($[***]) in Net Sales from the Sale of Licensed
Product. 

	 	(c)	 [***] dollars ($[***]) upon achieving the first [***] dollars ($[***]) in Net Sales from the Sale of Licensed
Product. 

 LICENSEE shall notify LICENSOR within [***] of LICENSEE’s determination of the occurrence of each such
event and shall remit payment due under this Section within [***] of providing such notice to LICENSOR. Payments made pursuant to this Section 6.2 shall be nonrefundable and shall not be creditable against any other fee or payment. For purposes
of this Section 6.2, [***]. For purposes of example and without limitation, [***]. Similarly, if, instead of [***]. In addition, [***] for purposes of this Section 6.2. 

 

	6.3	 Sales or transfers to LICENSEE’s Affiliates or Sublicensees shall not be included in the calculation of
Net Sales until the actual Sale and shipment by such Affiliate or Sublicensee to a Third Party, except if such Affiliate or Sublicensee is an End User of the Licensed Product. Under such circumstances where an Affiliate or Sublicensee of LICENSEE is
an End User, Net Sales shall be based on the lowest Sales price of Licensed Product charged to Third Parties for the calendar quarter in which the Licensed Product is shipped to such Affiliate or Sublicensee and which calendar quarter shall be
deemed the calendar quarter of payment, taking into account volumes of purchases. 

  

	6.4	 The LICENSEE agrees to pay all bank transfer charges, and all taxes, fees and other governmental charges
imposed on the payments to the LICENSOR pursuant to the terms and conditions of this Agreement (excluding any income tax or similar tax imposed on LICENSOR as a result of its receipt of payments hereunder). 

  
 7 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
  

	6.5	 All payments under this Agreement should be made payable to “Georgetown University” and sent to the
address identified in Section 17.1 herein. Each payment should reference this Agreement and identify the obligation under this Agreement that the payment satisfies. 

 

	6.6	 All payments due under this Agreement shall be drawn on a United States bank and shall be payable in United
States dollars. Conversion of foreign currency to U.S. dollars for purposes of calculating Net Sales shall be made in accordance with LICENSEE’s then customary and usual currency conversion procedures, consistently applied, which shall be
consistent with LICENSEE’s usual and customary generally accepted accounting principles consistently applied and which procedures shall be disclosed to LICENSOR. Such payments shall be without deduction of exchange, collection, or other
charges, and, specifically, without deduction of withholding or similar taxes or other government imposed fees or taxes, except as permitted in the definition of Net Sales. 

 

	6.7	 Any payments by LICENSEE that are not paid on or before the date such payments are due under this Agreement
shall bear interest, to the extent permitted by law, at an annual rate equal to one percentage point above the U.S. prime rate of interest as reported in the Wall Street Journal on the date payment is due, with interest accruing on a daily basis.

 ARTICLE 7 

Reports and Records of Licensee 
  

	7.1	 Frequency of Reports.  

(a)    Before First Commercial Sale. Prior to First Commercial Sale of any Licensed Product, LICENSEE shall deliver
progress reports to LICENSOR annually, within [***] after the end of each calendar year. Such progress reports shall describe for each Licensed Product the LICENSEE’s work related to the development and testing of the Licensed Product and its
efforts in obtaining any required government approvals for marketing the Licensed Product. Each report will include information sufficient to enable the LICENSOR to determine the LICENSEE’s progress in commercially developing the Licensed
Product, including a summary of any material work completed by LICENSEE during such calendar year and any material work planned to be conducted by LICENSEE during the subsequent calendar year, with respect to the Licensed Product. In the event
LICENSOR, in good faith, does not reasonably deem the information set forth in the report sufficient for determining progress in commercially developing the Licensed Product, LICENSEE shall modify the report accordingly. 

(b)    Upon First Commercial Sale of a Licensed Product. LICENSEE shall report to LICENSOR the date of First
Commercial Sale of a Licensed Product within [***] of its determination of the occurrence thereof. 

  
 8 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
 (c)    After First Commercial
Sale.    After the First Commercial Sale of a Licensed Product and until the payment of all of the milestone payments in Section 6.2 for such Licensed Product, LICENSEE shall deliver a report to LICENSOR within [***]
days after December 31 of each year of Net Sales from the Sale of such Licensed Product during the immediately preceding [***] period containing the information concerning the immediately preceding [***] period, as further described in
Section 7.2(b). 
  

	7.2	 Reports and Payments.  

 

	 	(a)	 LICENSEE shall keep full, true and accurate books and records which shall contain all information that may be
reasonably necessary for the purpose of showing LICENSEE’s compliance with this Agreement, including without limitation, the amounts payable to LICENSOR hereunder. Said books of account shall be kept at LICENSEE’s principal place of
business. Said books and the supporting data shall be open to inspection on behalf of LICENSOR upon no less than [***] days written notice during reasonable business hours to the extent necessary for the purpose of verifying LICENSEE’s
statement of Net Sales provided under Section 7.2(b) or compliance in other respects with this Agreement. Such inspection shall be made not more often than once each calendar year at the expense of LICENSOR by an independent Certified Public
Accountant appointed by LICENSOR and to whom LICENSEE has no reasonable objection. LICENSEE shall not be required to retain such records for more than [***] after the date such records have been created. Notwithstanding the foregoing, in the event
that the payment due date for any milestone payment herein is determined by the independent Certified Public Accountant to have been due at a date more than [***] earlier than determined by LICENSEE, then unless LICENSEE disputes such determination
(pursuant to the process set forth in Section 7.2(a)(i) below), LICENSEE shall, within [***] of such Certified Public Accountant’s determination, remit the milestone payment due (if not previously paid) and reimburse LICENSOR for the
reasonable, out-of-pocket costs of the audit incurred by LICENSOR. If LICENSEE disputes the Certified Public Accountant’s determination and such dispute is resolved
against LICENSEE, then Licensee shall, within [***] of the conclusion of such dispute resolution, remit the milestone payment due (if not previously paid) and reimburse LICENSOR for the reasonable, out-of-pocket costs of the audit incurred by LICENSOR. 

  

	 	(i)	 LICENSEE may dispute a determination made by LICENSOR’s Certified Public Accountant pursuant to this
Section 7.2(a) by providing written notice to LICENSOR of such dispute within [***] of LICENSEE’s receipt of such Certified Public Accountant’s determination. If LICENSEE commences such dispute, the disputed determination shall be
decided by an independent expert having at least ten (10) years 

  
 9 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 

	 	professional experience in the calculation of net sales of pharmaceutical products. The Parties shall reasonably cooperate with the expert’s investigation of the dispute. The decision of the expert shall be final
and binding. If the expert rules in favor of LICENSEE, then the costs and expenses of the expert shall be paid by LICENSOR, and if the expert rules in favor of LICENSOR, then the costs and expenses of the expert shall be paid by LICENSEE.

  

	 	(b)	 LICENSEE shall, within [***] days after December 31 of each year, to the extent required under
Section 7.1(c), deliver to LICENSOR a full and detailed report for the preceding [***] period setting forth the Net Sales of each of LICENSEE and Affiliate, and each Sublicensee of LICENSEE , including at least the following information:

  

	 	(i)	 Total amount invoiced for Licensed Product Sold; and 

	 	(ii)	 Deductions applicable as provided in the definition of Net Sales. 

ARTICLE 8 
 Patents and
Intellectual Property Rights 
  

	8.1	 Patent Prosecution. LICENSEE shall have the first right, but not the obligation, to prepare, file,
prosecute (including to seek extensions of), maintain and defend all pending patent applications and patents comprising Licensed Patents (including any inter partes and opposition proceedings relative to Licensed Patents). LICENSOR shall
reasonably cooperate with LICENSEE in the filing, prosecution, maintenance and defense of the Licensed Patents. Such cooperation includes promptly executing all documents, or requiring inventors, subcontractors, employees and consultants and agents
of LICENSOR and its Affiliates to execute all documents, and joining as a party in any proceedings, as reasonable and appropriate so as to enable the filing, prosecution, maintenance and defense of any Licensed Patents in any country. If LICENSEE
elects not to file, prosecute, maintain and defend any of the Licensed Patents, LICENSOR may (but shall not be obligated to), upon notice to LICENSEE, undertake such filing, prosecution, maintenance and defense of such Licensed Patents at
LICENSOR’s sole cost and expense, subject to LICENSEE’s prior written consent, not to be unreasonably withheld. LICENSEE may prepare, file, prosecute, maintain and defend all Licensed Patents using counsel of its choice. In the event that
LICENSEE changes counsel for any reason, LICENSEE shall replace such counsel with new counsel of its choice that is reasonably acceptable to LICENSOR, provided, however, that if LICENSOR rejects the choice of new counsel by LICENSEE [***], then
LICENSEE shall be free, in its sole discretion, 

  
 10 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 

	 	to choose an attorney of its choice. LICENSEE shall instruct counsel to promptly provide LICENSOR with copies of all relevant documentation so that LICENSOR may be currently and promptly informed and appraised of the
prosecution of Licensed Patents, but in no case [***] in advance of any deadline for filing a response, and so that LICENSOR may comment upon such documentation sufficiently in advance of any final deadline for filing a response, provided, however,
that if LICENSOR has not commented upon such documentation [***] to the final deadline for filing a response, LICENSEE shall be free to respond appropriately without waiting for LICENSOR’s comments, if any. LICENSEE shall, in good faith,
consider all reasonable comments provided by LICENSOR. LICENSEE shall not finally and irrevocably cancel all Valid Claims in a Licensed Patent without LICENSOR’s prior written consent, not to be unreasonably withheld, it being understood that
abandonment of a Licensed Patent shall not be deemed a cancellation of all Valid Claims in such Licensed Patent if a continuation or similar application claiming priority (directly or indirectly) to such Licensed Patent is filed and which
continuation or other application includes one or more Valid Claims of the abandoned Licensed Patent. Both parties hereto shall keep this documentation in confidence in accordance with the provisions of Article 12 herein. 

 

	8.2	 Costs. Except as provided in Section 8.1, all costs, including without limitation attorneys’
fees, incurred by LICENSEE for preparing, filing, prosecuting, copying LICENSOR, and maintaining and defending the Licensed Patents, whether incurred prior to or after the Effective Date, shall be borne by LICENSEE. The costs of all oppositions
initiated or defended by LICENSEE shall be considered prosecution expenses and also shall be borne by LICENSEE. 

  

	8.3	 Duration of Obligation. LICENSEE’s obligation to pay costs as set forth in this Article 8 shall
continue until [***] after receipt by either Party of a Notice of Termination or expiration of this Agreement. 

  

	8.4	 Communication between Parties. Each Party shall promptly inform the other as to all matters that come to
its attention that reasonably could be expected to materially adversely affect the prosecution, maintenance or defense of the Licensed Patents. 

ARTICLE 9 
 Patent
Marking 
 Patent Marking. LICENSEE shall mark the Licensed Products with a patent notice referring to the Licensed Patents in accordance with 35
U.S.C. §287. 

  
 11 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
 ARTICLE 10 

Enforcement of the Licensor’s Intellectual Property 
  

	10.1	 Third Party Infringement. Each Party shall inform the other Party promptly in writing of any alleged
infringement of the Licensed Patents by a Third Party and of any available evidence thereof. 

  

	10.2	 During the term of this Agreement, LICENSEE shall have the initial right, but not the obligation, to prosecute
at its own expense any infringement of the Licensed Patents. If LICENSEE prosecutes any infringement, LICENSOR agrees that LICENSEE may include LICENSOR as a co-plaintiff in any such suit, and LICENSOR agrees
to join in any such suit, without any expense to LICENSOR. The total cost of any infringement action commenced or defended by LICENSEE shall be borne by LICENSEE and LICENSEE shall keep all recovery or damages derived therefrom.

  

	10.3	 If after [***] of having been notified of any alleged infringement of the Licensed Patents or such shorter time
proscribed by law, LICENSEE: 

  

	 	(a)	 has been unsuccessful in persuading the alleged infringer to desist, or 

 

	 	(b)	 has not brought and has not been diligently prosecuting an infringement action, or 

 

	 	(c)	 if LICENSEE notifies LICENSOR at any time prior thereto of its intention not to bring suit against any alleged
infringer, then, and in those events only, and subject to the rights of other co-owners of the Licensed Patents, LICENSOR shall have the right, but not the obligation, to prosecute at its own expense any
infringement of the Licensed Patents, and LICENSOR may, for such purposes, require joinder of LICENSEE as involuntary parties to the litigation, provided, however, that such right to bring an infringement action remains in effect only for so long as
the license granted herein remains exclusive. No settlement, consent judgment or other voluntary final disposition of the suit may be entered into without the consent of LICENSEE which consent shall not unreasonably be withheld, conditioned or
delayed. LICENSOR shall indemnify LICENSEE against any order for costs that may be made against LICENSEE in such proceedings or any action arising there from, including without limitation, abuse of process and malicious prosecution. The total cost
of any infringement action commenced or defended by LICENSOR shall be borne by LICENSOR and, subject to the rights of other co-owners of the Licensed Patents, LICENSOR shall keep all recovery or damages for
past infringement derived therefrom. 

  

	10.4	 In any infringement suit as either Party may institute to enforce the Licensed Patents pursuant to this
Agreement, the other Party hereto shall, at the request and expense of the Party initiating such suit, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, papers,
information, samples, specimens, and the like. 

  
 12 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
 ARTICLE 11 

Indemnification and Insurance 
  

	11.1	 LICENSOR’s Right to Indemnification. LICENSEE shall indemnify, defend and hold harmless LICENSOR,
its directors, trustees, officers, faculty, employees, students, and agents and their respective successors, heirs and assignees (the “Indemnitees”), against any and all claims, suits, losses, liabilities, damages, costs, fees and
expenses, including reasonable attorneys’ fees and expenses, incurred by or imposed upon any of the Indemnitees in connection with any claims, suits, actions or demands of Third Parties (“Claims”) asserted against them to the extent
arising out of any theory of liability (including without limitation actions in the form of tort, product liability, negligence, warranty, strict liability, violation of government regulation, infringement of patent or other proprietary rights,
breach of any representations or warranties by LICENSEE, failure by LICENSEE to perform any of its obligations under this Agreement, trademark or trade dress infringement arising out of the use of any trademark or trade dress by LICENSEE in
connection with the Sale of Licensed Product, copyright infringement arising out of any material published by LICENSEE, and regardless of whether such action has any factual basis) concerning any Licensed Product that is made, used, Sold,
distributed, supplied or provided, or any Licensed Method performed, pursuant to any right or license granted under this Agreement or any Sublicense, except to the extent that any Claims shall have arisen from the gross negligence or willful
misconduct of any LICENSOR Indemnitee or the breach of this Agreement by any LICENSOR Indemnitee. 

 LICENSOR Indemnitee
shall promptly notify LICENSEE of any Claim with respect to which such LICENSOR Indemnitee is seeking indemnification hereunder, upon becoming aware thereof, and permit LICENSEE at LICENSEE’s cost to defend against such Claim and shall
cooperate in the defense thereof. Neither such LICENSOR Indemnitee nor LICENSEE shall enter into, or permit, any settlement of any such Claim without the express written consent of the other Party, which shall not unreasonably be withheld,
conditioned or delayed. Such LICENSOR Indemnitee may, at its option and expense, have its own counsel participate in any proceeding which is under direction of LICENSEE and will cooperate with LICENSEE and its insurer in the disposition of any such
matter; provided, however, that if LICENSEE shall not defend such Claim, such LICENSOR Indemnitee shall have the right to defend such Claim itself and recover from LICENSEE all reasonable attorneys’ fees and expenses incurred by it during the
course of such defense. 
  

	11.2	 Failure to Defend. With respect to any Claim which pursuant to Section 11.1, LICENSEE shall fail to
defend, LICENSEE shall not thereafter question the liability of LICENSEE hereunder to the Indemnitee for any loss (including reasonable counsel fees and other reasonable expenses of defense) arising from such Claim. 

  
 13 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
  

	11.3	 Claims Period. Notwithstanding the foregoing, the indemnification provisions of Section 11.1 hereof
shall survive termination or expiration of this Agreement, but only with respect to claims which arose from acts or circumstances which occurred prior to termination. 

 

	11.4	 Insurance. LICENSEE shall obtain and carry in full force and effect, or shall provide through
self-insurance, commercial general liability insurance, including product liability and errors and omissions insurance, which shall protect LICENSEE and Indemnitees with respect to events covered by Section 11.1 above. Such insurance
(i) shall list LICENSOR as an additional insured thereunder, (ii) shall be endorsed to include product liability coverage, and (iii) shall require [***] written notice to be given to LICENSOR prior to any cancellation or material
change thereof. The limits of such insurance shall be consistent with limits as are customary in the U.S. pharmaceutical industry for the activities to be conducted by LICENSEE under this Agreement. LICENSEE shall provide LICENSOR with Certificates
of Insurance evidencing compliance with this Section. LICENSEE shall continue to maintain such insurance or self-insurance after the expiration or termination of this Agreement during any period in which LICENSEE or any SUBLICENSEE continues to
make, use, or Sell a product that was a Licensed Product under this Agreement, and thereafter for a period of [***]. 

ARTICLE 12 

Confidentiality Provisions 
  

	12.1	 Confidential Information. All information disclosed by one Party to another Party hereunder
(“Confidential Information”) shall be maintained in confidence by the receiving Party and shall not be disclosed to any Third Party or used for any purpose other than performance of its obligations and exercise of its rights under this
Agreement (“Permitted Purpose”) without the prior written consent of the disclosing Party for the term of this Agreement and a period of [***] thereafter, except to the extent that such information is: 

 

	 	(i)	 now in the public domain or subsequently enters into the public domain through no fault of the receiving Party;

  

	 	(ii)	 known by the receiving Party at the time of its receipt and not through a prior disclosure by the disclosing
Party on a confidential basis as documented by the receiving Party’s written records; 

  

	 	(iii)	 developed by or for the receiving Party independently of Confidential Information received from the disclosing
Party as documented by the receiving Party’s written records; 

  
 14 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 

	 	(iv)	 subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is not under an
obligation of confidentiality to the disclosing Party; 

  

	 	(v)	 disclosed to governmental or other regulatory agencies in order to obtain patents or to gain or maintain
approval to conduct clinical trials or to market and Sell Licensed Products or perform Licensed Methods, but such disclosure may be only to the extent reasonably necessary to obtain patents or authorizations; and/or 

 

	 	(vi)	 deemed necessary by LICENSEE to be disclosed to Sublicensees, agents, consultants, and/or other Third Parties
for the development and/or commercialization of Licensed Products and/or in connection with a licensing transaction and/or a permitted assignment under this Agreement, and/or loan, financing, or investment and/or acquisition, merger, consolidation,
or similar transaction (or for such entities to determine their interest in performing such activities) in each case on the condition that any third parties to whom such disclosures are made agree to be bound by confidentiality and non-use obligations substantially similar to those contained in this Agreement. 

Confidential Information pertaining to the Licensed Patents shall be deemed Confidential Information of both Parties. 

 

	12.2	 Each Party shall keep in confidence and shall each use its Commercially Reasonable Efforts to cause its
respective officers, directors, employees, professors, researchers, students, trustees, regents, agents, consultants, clinical research associates and clinical investigators to whom it is permitted to disclose information pursuant to the terms of
this Agreement to retain in confidence all Confidential Information of the disclosing Party and not use such Confidential Information for any purpose other than the Permitted Purpose. Without limiting the foregoing, each Party shall exercise the
same degree of diligence and care with respect to the Confidential Information of the disclosing Party as it exercises with respect to its own confidential and proprietary information. 

 

	12.3	 If a Party is required by judicial or administrative process to disclose Confidential Information that is
subject to the non-disclosure provisions of this Article 12, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to
challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions
hereof, and the disclosing Party, pursuant to law or court order, shall take all steps reasonably necessary, including without limitation obtaining an order of confidentiality, to ensure the continued confidential treatment of such Confidential
Information. 

  
 15 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
  

	12.4	 Either Party may disclose the terms of this Agreement to the extent required, in the reasonable opinion of such
Party’s legal counsel, to comply with applicable laws, including without limitation the rules and regulations promulgated by the United States Securities And Exchange Commission. Notwithstanding the foregoing, prior to such disclosure, the
Parties will consult with one another on the terms of this Agreement that are to be redacted in making any such disclosure. If a Party discloses this Agreement or any of the terms hereof in accordance with this Section, such Party agrees, at its own
expense, to seek confidential treatment of portions of this Agreement or such terms as may be reasonably requested by the other Party. 

  

	12.5	 Publicity. No Party will make any media release or other public announcement relating to or referring to
this Agreement without the prior written consent of the other Party. 

 ARTICLE 13 

Representation or Warranties; Disclaimer 
  

	13.1	 Warranties. LICENSOR represents and warrants to Licensee that: 

(a)    LICENSOR has full right and authority to enter into this Agreement and to grant the licenses and other rights to
LICENSEE as herein described; 
 (b)    to the best of LICENSOR’s knowledge after reasonably due inquiry, the
execution, delivery and performance of this Agreement does not conflict with any other agreement, contract, instrument or understanding, oral or written, to which LICENSOR is a party, or by which it is bound; and 

(c)    none of LICENSOR or any of its Affiliates has entered into any agreement or otherwise licensed, granted, assigned,
transferred, conveyed or otherwise encumbered or disposed of any right, title or interest in or to any of the Licensed Patents that would conflict with or impair the scope of any rights or licenses granted hereunder. 

 

	13.2	 Except as may otherwise be expressly set forth in this Agreement, LICENSOR makes no representation and extends
no warranties of any kind concerning the Licensed Patents, express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, noninfringement, validity of Licensed Patents claims, whether issued or
pending, and the absence of latent or other defects, whether or not discoverable. Specifically, and not to limit the foregoing, LICENSOR makes no warranty or representation (i) regarding the validity or scope of the Licensed Patents,
(ii) that the exploitation of the Licensed Patents or any Licensed Product or Licensed Method will not infringe any patents or other intellectual property rights of LICENSOR or of a Third Party and (iii) that the Licensed Products will be
safe or non-hazardous. 

  
 16 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
  

	13.3	 In no event shall LICENSOR, its trustees, directors, officers, employees and Affiliates, under any
circumstances, be liable or obligated in any manner for any special, incidental, consequential or exemplary damages arising out of or related to this Agreement or the transactions contemplated hereunder, even if LICENSOR is informed in advance of
the possibility of such damages occurring. This limitation is separate and independent of any other remedy limitations and shall not fail if such other limitation on remedy fails. 

 

	13.4	 LICENSEE hereby represents and warrants to LICENSOR that LICENSEE has the right, power and authority to enter
in to this Agreement and to fully perform all of its obligations hereunder; and entering into this Agreement does not violate any agreement or obligation existing between LICENSEE and any Third Party. 

ARTICLE 14 
 Assignment

 LICENSEE may not assign, voluntarily, by operation of law, or otherwise, this Agreement without LICENSOR’s prior written
consent, and any attempt to do so without such consent will be void and of no effect, except that LICENSEE may assign its rights and obligations under this Agreement without LICENSOR’s consent to an Affiliate of LICENSEE or to a successor of
LICENSEE in connection with the merger, consolidation, or sale of all or substantially all of LICENSEE’s assets or equity or that portion of its business to which this Agreement relates, which assignment shall be disclosed to LICENSOR by
written notice as soon as possible, but in no event no longer than [***] after the assignment is effective. 
 ARTICLE 15 

Compliance with the Law 
  

	15.1	 LICENSEE shall use Commercially Reasonable Efforts to comply with all commercially material local, state,
federal, and international laws and regulations relating to the development, manufacture, use and Sale of Licensed Products. 

  

	15.2	 LICENSEE acknowledges that it is subject to the United States laws and regulations controlling the export of
technical data, computer software, laboratory prototypes and other commodities. The transfer of such items may require a license from the cognizant agency of the United States Government and written assurances by LICENSEE that LICENSEE shall not
export data or commodities to certain foreign countries without prior approval of such agency. LICENSOR neither represents that a license shall not be required nor that, if required, it shall be issued. 

  
 17 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
 ARTICLE 16 

Term and Termination 
  

	16.1	 Term of License. Unless sooner terminated pursuant to another provision of this Agreement, this
Agreement shall continue in full force and effect and shall have a term expiring upon the last expiration or last final invalidation of the Licensed Patents, including any extension or reissues thereof. 

 

	16.2	 Voluntary Termination by LICENSEE. LICENSEE shall have the right to terminate this Agreement, for any
reason upon at least sixty (60) days’ prior written notice to LICENSOR, such notice to state the date, at least sixty (60) days in the future, upon which termination is to be effective. 

 

	16.3	 Termination for Default. LICENSOR may terminate this Agreement and the license granted hereunder or
render this license non-exclusive, effective upon written notice from LICENSOR to LICENSEE, for any of the following: 

  

	 	(a)	 If LICENSEE does not make a payment due hereunder and fails to cure such nonpayment (including the payment of
interest) within thirty (30) days after the date of notice of such nonpayment by LICENSOR; 

  

	 	(b)	 If LICENSEE defaults in its obligations to procure and maintain insurance in accordance with Section 11.4
and does not cure such failure within forty-five (45) days after the date of notice of such failure by LICENSOR; or 

  

	 	(c)	 If LICENSEE shall become insolvent, shall make an assignment for the benefit of creditors, or shall have a
petition in bankruptcy filed for or against it that is not dismissed within sixty (60) days of filing or if a receiver, trustee, or any similar officer is appointed to take possession, custody, or control of all or substantially all of
LICENSEE’s assets or property or if LICENSEE adopts any resolution of its Board of Directors or stockholders for the purpose of effecting any of the foregoing. 

 

	16.4	 Except as provided for in Section 16.3(a) through 16.3(c) above, if LICENSEE materially defaults in the
performance of any material obligations under this Agreement (including its obligations under Article 5) and the default has not been cured within [***] after the date of written notice of such default by LICENSOR, LICENSOR may terminate this
Agreement and the license granted hereunder or render this license non-exclusive. Such termination rights shall be in addition to and not in substitution for any other remedies that may be available to
LICENSOR. Termination pursuant to this Section 16.4 shall not relieve the LICENSEE from liability and damages to LICENSOR for breach of this Agreement. 

  
 18 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
  

	16.5	 If LICENSEE in good faith disagrees as to whether there has been a default under Section 16.3 or
Section 16.4, (a) LICENSEE shall provide written notice to LICENSOR that it disputes such claim of default within [***] of receipt of the written notice of default from LICENSOR, (b) LICENSEE may contest the allegation of default in a
court of competent jurisdiction, (c) from the date of receipt of such notice by LICENSOR until such time as the dispute has become finally settled, the running of the time periods as to which LICENSEE must cure such alleged default shall be
suspended, and (d) LICENSOR shall not have the right to terminate this Agreement unless and until the existence of such default has been determined. It is understood and acknowledged that during the pendency of such a dispute, all of the terms
and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder. 

  

	16.6	 Waiver by either Party of a single default or a succession of defaults shall not deprive such Party of any
right to terminate this Agreement arising by reason of any subsequent default. 

  

	16.7	 Patent Challenge on Sublicensed Patents. LICENSEE shall include provisions in all agreements granting
Sublicenses of LICENSEE’s rights hereunder (excluding Sublicenses with Third Party Contractors) providing that if the Sublicensee undertakes a challenge in a legal or administrative proceeding to the validity, patentability or enforceability of
any of the Licensed Patents or otherwise opposing in a legal or administrative proceeding any of the Licensed Patents (each a “Patent Challenge”) with respect to which the Sublicensee is Sublicensed, LICENSEE shall be permitted to
terminate such Sublicense. If a Sublicensee of LICENSEE undertakes a Patent Challenge of any such Licensed Patent under which such Sublicensee is Sublicensed, then LICENSEE within [***] after receipt of notice from LICENSOR of such Patent Challenge
demanding termination of the Sublicense shall terminate the applicable Sublicense agreement. If LICENSEE fails to so terminate such Sublicense agreement, LICENSOR may terminate this Agreement. 

 

	16.8	 Effect of Termination. 

 

	 	(a)	 Termination of Licensee’s Rights. Upon termination of this Agreement, the license granted hereunder
shall terminate and all of the Parties’ rights granted under this Agreement shall immediately terminate. Any such termination shall not relieve either Party from any obligations accrued prior to the date of such termination. For clarity,
termination of LICENSEE’s rights under this Agreement shall not affect LICENSEE’s rights as a co-owner of the Licensed Patents or rights obtained from other
co-owners of the Licensed Patents. 

  
 19 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
  

	 	(b)	 Upon termination, each Party shall promptly return to the other Party, or destroy, all Confidential Information
of the other Party provided to it under this Agreement, regardless of medium, including without limitation, magnetically recorded writings or legible and readable copies thereof, which are in its possession, custody, or control, provided, however, a
Party shall not be obligated to return or destroy Confidential Information of the other Party which such Party can show that it independently developed or which is Confidential Information of both LICENSOR and LICENSEE. Notwithstanding the
foregoing, each Party may retain one copy of the Confidential Information of the other Party in its confidential legal files for the purpose of establishing the extent of the disclosure and its obligations hereunder. 

 

	 	(c)	 The provisions under which this Agreement may be terminated will be in addition to any and all other legal
remedies which either Party may have for the enforcement of any and all terms hereof, and do not in any way limit any other legal remedy such Party may have. 

  

	 	(d)	 The following provisions of this Agreement shall survive termination: Articles 1, 11, 12, 16.8, and 17 will
survive the termination of this Agreement. 

 ARTICLE 17 

Miscellaneous 
  

	17.1	 Notice. Any notices required or permitted under this Agreement shall be in writing, shall specifically
refer to this Agreement, and shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, confirmed electronic mail, or registered or certified mail, postage prepaid, return receipt requested, to the following
addresses or facsimile numbers of the Parties: 

 If to GEORGETOWN: 

By courier: 
 Vice President 

Office of Technology Commercialization 

Georgetown University 
 Harris
Building, Suite 1500 
 3300 Whitehaven Street, N.W. 

Washington, DC 20007 
 Fax: 202-687-3111 

  
 20 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
 By United States Postal Service: 

Vice President 
 Office of
Technology Commercialization 
 Georgetown University 

Box 571408 
 Washington, DC
20057-1408 
  

	 	If to X4:	 Attn: John Celebi 

Chief Operating Officer 
 X4
Pharmaceuticals, Inc. 
 784 Massachusetts Avenue, Suite 140 

Cambridge MA 02139 
 All notices
under this Agreement shall be deemed effective upon receipt. A Party may change its contact information immediately upon written notice to the other Parties in the manner provided in this Section. 

 

	17.2	 Governing Law. This Agreement and all disputes arising out of or related to this Agreement (whether in
contract, tort or otherwise), and the validity, performance, interpretation, enforcement, breach or termination hereof, and any remedies relating thereto, shall be governed by and construed in all respects under, the laws of the State of New York
without giving effect to its conflicts of law principles. 

  

	17.3	 Force Majeure. No Party shall be liable or responsible hereunder by reason of any failure or delay in
the performance of its obligations hereunder on account of strikes, shortages, riots, insurrection, fires, flood, storm, explosions, acts of God, war, governmental action, labor conditions, earthquakes, or any other cause which is beyond the
reasonable control of such Party. 

  

	17.4	 Further Assurances. Each Party agrees to cooperate fully with the other Parties and to execute such
further instruments, documents and agreements and to give such further written assurances, as may be reasonably requested by the other Party, to better evidence and reflect the transactions contemplated hereby, and to carry into effect the intent
and purposes of this Agreement. 

  

	17.5	 Amendment and Waiver. This Agreement may be amended, supplemented, or otherwise modified only by a
writing that refers explicitly to this Agreement and that is signed on behalf of all Parties. No term or provision hereof will be considered waived by a Party, and no breach excused by a Party, unless such waiver or consent is in writing signed on
behalf of the Party against whom the waiver is asserted. No consent by either Party to, or waiver of, a breach by either Party, whether express or implied, will constitute a consent to, waiver of, or excuse of any other different or subsequent
breach by a Party. 

  

	17.6	 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their
respective permitted successors and assigns. 

  
 21 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 
  

	17.7	 Non-Use of LICENSOR Name. LICENSEE and Sublicensees shall not
use the name of “Georgetown University,” or any variation, adaptation, or abbreviation thereof, or of any of its trustees, officers, faculty, students, employees, or agents, or any trademark, service mark, seal, mascots, crests or logo
owned by GEORGETOWN or any of its personnel, or any adaptation of them, or any terms of this Agreement in any promotional, advertising or sales literature or, except as permitted by Section 12.4, other public announcement or disclosure without
the prior written consent of Georgetown. The foregoing notwithstanding, without the consent of GEORGETOWN, LICENSEE may state that it is licensed by LICENSOR under one or more of its patents and/or patent applications comprising the Licensed
Patents. 

  

	17.8	 Equitable Relief. Each Party agrees that certain breaches of this Agreement by the other Party may
result in irreparable harm to the other Party, the extent of which would be difficult and/or impracticable to assess, and that money damages would not be an adequate remedy for such breach. Accordingly, the other Party shall be entitled to seek
immediate equitable and other provisional relief, including without limitation specific performance of this Agreement and a temporary restraining order and/or preliminary and/or permanent injunction, as a remedy for such breach in addition to any
and all other remedies available to a Party at law or in equity and without prejudice to any such other remedies. 

  

	17.9	 Relationship of Parties. Each Party’s relationship with the other is that of an independent
contractor, and nothing in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship. No Party is authorized to make any representation, contract or commitment on behalf of the
other. 

  

	17.10	 Severability. In the event that any provision of this Agreement shall be unenforceable or invalid under
any applicable law or be so held by applicable court decision, such unenforceability or invalidity shall not render this Agreement unenforceable or invalid as a whole, and, in such event, such provisions shall be changed and interpreted so as to
best accomplish the objectives of such unenforceable or invalid provision within the limits of applicable law or applicable court decisions. 

  

	17.11	 Headings. The paragraph headings appearing in this Agreement are inserted only as a matter of
convenience and in no way define, limit, construe or describe the scope or extent of such paragraph or in any way affect such paragraph. 

  

	17.12	 Counterparts. This Agreement may be signed in two or counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. If this Agreement is executed in counterparts, no 

  
 22 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 GU Reference: 2016-058 

 

	 	signatory hereto shall be bound until all of the Parties named below have duly executed or caused to be duly executed a counterpart of this Agreement. A signature on a copy of this Agreement received by either Party by
facsimile or PDF e-mail is binding upon the other Party as an original. The Parties agree that a photocopy of such facsimile or PDF e-mail may also be treated by the
Parties as a duplicate original. 

  

	17.13	 Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to
its subject matter and supersedes all prior agreements or understandings between the Parties relating to its subject matter. 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives. 

 

									
	GEORGETOWN UNIVERSITY:	 		 	X4 PHARMACEUTICALS, INC.:
					
	By:	 	/s/ Claudia Cherney Stewart	 		 	By:	 	/s/ John Celebi
	Name:	 	Claudia Cherney Stewart, Ph.D.	 		 	Name:	 	John Celebi
	Title:	 	Vice President, Office of Technology Commercialization	 		 	Title:	 	Chief Operating Officer
	Date:	 	12/13/2016	 		 	Date:	 	12/13/2016

  
 23 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.EX-10.8

 Exhibit 10.8 

BIDMC Agreement No: A9456 
 BIDMC
Case No: 1952 
 BETH ISRAEL DEACONESS MEDICAL CENTER 

EXCLUSIVE LICENSE AGREEMENT 

This License Agreement (“Agreement”) is made as of the date immediately above the signatures of the Parties below
(“Effective Date”) between Beth Israel Deaconess Medical Center, a not-for-profit Massachusetts corporation, with a principal place of operation
at 330 Brookline Avenue, Boston, Massachusetts 02215 (“BIDMC”), and X4 Pharmaceuticals, Inc. a corporation, having a principal place of business at 784 Massachusetts Avenue, Suite 140, Cambridge MA 02139
(“Licensee”), each referred to individually as a “Party” and collectively as the “Parties”. 

RECITALS 
 BIDMC, as a
center for patient care, research and education, owns certain Patent Rights (defined below) through assignment and desires to benefit the public by disseminating the results of its research through the grant of a license of those Patent Rights to
Licensee for the commercial development, manufacture, distribution and use of Products and Processes (defined below). 
 Licensee has the
capability to commercially develop, manufacture, distribute and use Products and Processes for public use and benefit and desires to receive a license to such Patent Rights. 

For good and valuable consideration, the sufficiency of which the Parties acknowledge, the Parties agree as follows: 

1. DEFINITIONS 
 The
following terms have the following meanings: 
 1.1    “Affiliate” with respect to either Party, means
any corporation or other legal entity other than that Party, in whatever country organized, that directly or indirectly controls, is controlled by or is under common control with that Party. For the purposes of this definition, the term
“control” means (a) for Licensee, (i) beneficial ownership of at least fifty percent (50%) of the voting securities of a corporation or other business organization with voting securities or (ii) a fifty percent (50%) or
greater interest in the net assets or profits of a partnership or other business organization without voting securities; and (b) for BIDMC, the power, direct or indirect, to elect or appoint fifty percent (50%) or more of the directors or
trustees, or to cause direction of management and policies, whether through the ownership of voting securities, by contract or otherwise. 

  
 1 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 1.2    “Claim” means any pending or issued claim of any
Patent Right that has not been permanently revoked, nor held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction that is unappealable or unappealed in the time allowed for appeal. 

1.3    “Distributor” means any entity to whom Licensee, a Licensee Affiliate or a Sublicensee has granted,
express or implied, the right to Sell and/or distribute any Product or Process on behalf of Licensee, such Licensee Affiliate or such Sublicensee, without granting such entity the right to make, have made, use or have used. A Distributor shall not
be considered a Sublicensee under this Agreement. 
 1.4    “Field” means all fields of use. 

1.5    “Patent Costs” means all costs and expenses of any kind, including attorneys’ fees, associated
with the preparation, filing, prosecution and maintenance of all Patent Rights. 
 1.6    “Patent
Challenge” means a challenge in a legal or administrative proceeding to the validity, patentability or enforceability of any of the Patent Rights or otherwise opposing in a legal or administrative proceeding any of the Patent Rights. 

1.7    “Patent Rights” means the United States and international patents, patent applications and
provisional applications listed on Appendix A, and the patents resulting from any of the foregoing applications; and any divisions, continuations, and
continuations-in-part (but only to the extent the claims are directed to subject matter specifically described in the patent applications listed in Appendix A),
including foreign patent applications or patents that are equivalent to the foregoing; and any reissues, reexaminations or extensions of any of the foregoing; and any and all patents and patent applications claiming priority benefit from or to any
of the foregoing, and all patents and patent applications from which any of the foregoing claim priority benefit from or to. 

1.8    “Process” means any process, method or service the use or performance of which, in whole or in
part, is (a) covered by any Claim in the Patent Rights; or (b) which, absent the license granted hereunder, would infringe one or more Claims of the Patent Rights. 

1.9    “Product” means 

(a)    any product (including any apparatus or kit) that in whole or through a component part thereof, the manufacture,
use, practice or Sale of which is covered by one or more Claims of the Patent Rights or, in the absence of a license from BIDMC, would infringe one or more Claims of the Patent Rights; or 

(b)    any product (including any apparatus or kit) that is developed, produced or manufactured with, or used pursuant to,
a Process as defined in Section 1.9. 

  
 2 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 1.10    “Related Information” means any research data,
designs, formulae, process information and other information pertaining to any invention claimed in the Patent Rights owned by BIDMC, for which there is no obligation to any third party, and (i) is known as of the Effective Date and disclosed
to the BIDMC Technology Ventures Office by Dr. Mier; and (ii) is in addition to the disclosures in the patent application for the Patent Rights. Licensee shall maintain all such Related Information as the Confidential Information of BIDMC.

 1.11    “Sale” (and “Sell” and “Sold” as the case may be) shall mean to sell or
have sold, to lease or have leased, to import or have imported or otherwise to transfer or have transferred a Product or Process for consideration (in the form of cash or otherwise), and further in the case of a Process to use or perform such
Process in exchange for consideration for the benefit of a third party. 
 1.12    “Sublicensee” means
any sublicensee of the rights granted to Licensee pursuant to Section 2.1(a). Sublicensee shall not include Distributors. 

1.13    “Term” means the term of this Agreement, which shall commence on the Effective Date and shall
remain in effect until the date on which all issued patents and filed patent applications within the Patent Rights have expired or been permanently abandoned, unless this Agreement is terminated earlier as provided herein. 

1.14    “Territory” means worldwide. 

2. LICENSE 

2.1    Grant of License. 

(a)    Subject to the terms of this Agreement and BIDMC’s rights in the Patent Rights, BIDMC hereby grants to Licensee
and its Affiliates in the Field in the Territory for the Term, an exclusive, royalty-free, fully paid-up (upon payment of the License Issue Fee pursuant to Section 3.1) license under BIDMC’s rights
in the Patent Rights to make, have made, use, have used, Sell and have Sold Products and Processes. 
 (b)    Subject to
the terms of this Agreement and specifically Section 2.2, BIDMC grants Licensee the right to grant sublicenses under the rights granted in Section 2.1(a) and Section 2.1(c), provided that in each case Licensee shall be responsible for
the performance of any obligations of Sublicensees relevant to this Agreement as if such performance were carried out by Licensee itself, which right to grant sublicenses will be exclusive with respect to the rights granted in Section 2.1(a)
and will be non-exclusive with respect to the rights granted in Section 2.1(c). 

(c)    Subject to the terms of this Agreement, BIDMC hereby grants to Licensee and its Affiliates (subject to
Section 2.1(e)) in the Field in the Territory for the 

  
 3 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
Term, a nonexclusive royalty-free, fully paid-up (upon payment of the License Issue Fee pursuant to Section 3.1) right to use Related Information
disclosed by BIDMC to Licensee to develop, make, have made, use, have used, Sell and have Sold and otherwise commercialize the Products and Processes. 

(d)    The licenses granted in Sections 2.1(a) and 2.1(c) above include: 

 

	 	(i)	 the right to grant to the purchaser, user or consumer of Products the right to use such purchased Products in a
method coming within the scope of Patent Rights, and such purchasers, users and consumers will not be considered Sublicensees hereunder; and 

  

	 	(ii)	 the right to grant a Distributor the right to Sell (but not to make, have made, use or have used) such Products
and/or Processes for or on behalf of Licensee, Licensee Affiliates and Sublicensees in a manner consistent with this Agreement. 

(e)    The foregoing license grants to Licensee Affiliates are subject to each such 

Affiliate assuming the same obligations as those of Licensee and becoming subject to the same terms and conditions under this Agreement; and
further provided that Licensee shall be responsible for the performance of all of such obligations and for compliance with all of such terms and conditions by Affiliate. 

2.2    Sublicenses. Each sublicense granted hereunder shall be consistent with and comply with all terms of this
Agreement, and shall incorporate terms and conditions sufficient to enable Licensee to comply with this Agreement. Licensee shall provide to BIDMC a fully signed copy of all sublicense agreements and amendments thereto, including all exhibits,
attachments and related documents, within [***] of executing the same, excluding sublicenses granted to third parties that are clinical research organizations, contract manufacturers, contract laboratory organizations, and other similar third
parties that support the development and commercialization of Products and/or Processes on a fee-for-service basis as Sublicensees hereunder (“Third Party
Contractors”). Licensee will be permitted to redact from such fully signed copies proprietary and other sensitive information to the extent that such redaction does not impact BIDMC’s ability to confirm Licensee’s compliance with this
Agreement. Notwithstanding the foregoing, Licensee will disclose to BIDMC the identity of the Sublicensee (excluding, for avoidance of doubt, Third Party Contractors). Any sublicense which is not in accordance with the forgoing provisions shall be
null and void. Any Sublicensee and Distributor agreement under this Agreement shall provide for termination of any sublicense granted hereunder upon termination of this Agreement for any reason. Upon termination of this Agreement for any reason, any
Sublicensee and Distributor not then in default under its agreement shall have the right to seek a license from BIDMC. BIDMC agrees to negotiate such licenses in good faith under reasonable terms and conditions consistent with this Agreement. 

  
 4 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Upon Licensee’s request during the term of this Agreement, BIDMC agrees to provide, on
a timely basis, a letter to an existing or potential Sublicensee specifically named by Licensee stating that, in the event of termination of this Agreement, BIDMC will grant a license to Sublicensee under terms and conditions to be no less favorable
as a whole than those granted to Sublicensee by Licensee, provided that Sublicensee is not in default of its sublicense agreement with Licensee at the time such license is to be granted by BIDMC and provided that BIDMC shall not assume any
obligation of Licensee to Sublicensee under such agreement, except for the license granted. Licensee’s right to request and Sublicensee’s right to acquire such letter are specifically conditioned on BIDMC’s review of the final,
executed sublicense agreement between Sublicensee and Licensee and on BIDMC’s conclusion, at its reasonable discretion, that such sublicense agreement is reasonable and in the best interests of the commercialization of the Patent Rights. 

2.3    Retained Rights; Requirements. Any and all licenses granted hereunder are subject to: 

(a)    the royalty-free right of BIDMC and BIDMC’s Affiliates and of academic, government and not-for-profit institutions to make, use and/or practice the technology or method described and/or claimed in the Patent Rights solely for
non-commercial research purposes; and 
 (b)    for Patent Rights supported by
federal funding, the rights, conditions and limitations imposed by U.S. law (see 35 U.S.C. § 202 et seq. and regulations pertaining thereto), including without limitation: 

 

	 	(i)	 the royalty-free non-exclusive license granted to the U.S. government;
and 

  

	 	(ii)	 to the extent required by the National Institutes of Health (as the federal funding agency), the requirement
that any Products (if they qualify as “subject inventions” under 35 U.S.C. § 204) used or sold in the United States shall be manufactured substantially in the United States. 

If Licensee or any of its Affiliates or Sublicensees wishes to obtain a waiver of the requirement under Section 2.3(b)(ii), BIDMC agrees
to reasonably cooperate with Licensee or such Affiliates or Sublicensees in obtaining such waiver, including by directly filing for such waiver if required by applicable law and regulations. 

2.4    No Additional Rights. Nothing in this Agreement shall be construed to grant Licensee an express or implied
license under any patent, technology or intellectual property right owned solely or jointly by BIDMC, other than the Patent Rights and Related Information expressly licensed hereunder. 

  
 5 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 3. PAYMENTS 

3.1    License Issue Fee. Licensee shall pay BIDMC a non-refundable, non-creditable license issue fee in the sum of twenty thousand dollars ($20,000) (“License Issue Fee”) within twenty (20) business days of the Effective Date of this Agreement. For avoidance of doubt,
upon payment of the License Issue Fee, the licenses and rights granted to Licensee under Section 2.1 shall be fully paid-up and royalty-free. 

3.2    Form of Payment. All payments due under this Agreement shall be drawn on a United States bank and shall be
payable in United States dollars. Each payment shall reference this Agreement and identify the obligation under this Agreement that the payment satisfies. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing
in the United States, as reported in The Wall Street Journal, on the last working day of the applicable Reporting Period. Such payments shall be without deduction of exchange, collection or other charges, and, specifically, without deduction of
withholding or similar taxes or other government imposed fees or taxes. Checks for all payments due to BIDMC under this Agreement shall be made payable to BIDMC and addressed as set forth in Section 12.2. Payments via wire transfer should be
made as follows: 
 [***] 

3.3    Overdue Payments. The payments due under this Agreement shall, if overdue, bear interest at two percentage
Points above the Prime Rate of interest as reported in the Wall Street Journal on the date payment is due until payment thereof, not to exceed the maximum permitted by law. Any such overdue payments when made shall be accompanied by all interest so
accrued. Payment and acceptance, in whole or in part, of interest and the overdue payment shall not preclude BIDMC from exercising any other rights it may have as a consequence of the lateness of any payment. 

3.4    Consequences of a Patent Challenge. In the event that (i) Licensee, any of its Affiliates, or any
Sublicensee brings a Patent Challenge against BIDMC, or (ii) Licensee, any of its Affiliates, or any Sublicensee assists another party in bringing a Patent Challenge against BIDMC (except as required under a court order or subpoena), and
(iii) BIDMC does not choose to exercise its rights to terminate this Agreement pursuant to Section 9.4, then if such a Patent Challenge is successful, Licensee will have no right to recoup any monies paid during the period of challenge.

 4. PATENT PROSECUTION AND MAINTENANCE 

4.1    Prosecution. Provided that Licensee seeks and maintains the strongest and broadest patent claims reasonably
practicable and uses patent attorneys acceptable to BIDMC, such acceptance not to be unreasonably withheld, BIDMC appoints Licensee as its exclusive agent to prepare, file, prosecute (including to seek extensions of), maintain and defend (including
inter partes and opposition proceedings) all of the Patent Rights 

  
 6 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
during the Term. Licensee shall copy BIDMC on all patent prosecution documents and give BIDMC reasonable opportunities to advise Licensee on such filing, prosecution, maintenance and defense.
BIDMC shall reasonably cooperate with Licensee in the filing, prosecution, maintenance and defense of the Patent Rights. Such cooperation includes promptly executing all documents, or requiring inventors, subcontractors, employees and consultants
and agents of BIDMC and its Affiliates to execute all documents, and joining as a party in any proceedings, as reasonable and appropriate so as to enable the filing, prosecution, maintenance and defense of any Patent Right in any country. In the
event Licensee desires to abandon the prosecution, maintenance or defense of any patent, patent application, or any Claims within the Patent Rights where such Claims are not included in a continuation, divisional or other patent or patent
application, Licensee shall provide BIDMC with [***] prior written notice of such intended abandonment or decline of responsibility and, as to Claims, shall reasonably consider BIDMC’s judgment in whether or not to abandon or not defend such
Claim, and, as to such patent or patent application, such abandonment or election not to defend shall only be with prior notice to BIDMC on a patent by patent and country by country basis. If BIDMC desires to prosecute, maintain or defend any such
Patent Rights proposed to be abandoned by Licensee under this Agreement, the right to prepare, file, prosecute, maintain and defend the relevant Patent Rights shall revert, as between Licensor and Licensee, to BIDMC, at BIDMC’s expense, subject
to any third party rights. In such event, such BIDMC paid-for rights shall be removed from the definition of Patent Rights under this Agreement, the licenses granted to Licensee and its Affiliates as to such
Patent Rights shall terminate, and BIDMC shall have the right to abandon or maintain and license such Patent Rights in its discretion. 

4.2    Confidentiality of Prosecution and Maintenance Information. Each Party agrees to treat all information
related to prosecution and maintenance of Patent Rights as Confidential Information in accordance with the provisions of Appendix B. 
 5.
REPORTS 
 5.1    Progress Reports. Within [***] after the end of each calendar year, Licensee shall report
in writing to BIDMC on progress during such preceding [***] period in developing and/or commercializing Products and/or Processes, including, without limitation, progress on research and development, status of applications for regulatory approvals,
manufacturing, sales, sublicensing and the number of sublicenses (excluding Third Party Contractors) entered into and marketing. 
 6.
THIRD PARTY INFRINGEMENT AND LEGAL ACTIONS 
 6.1    Licensee Right to Prosecute. Licensee shall have the
first right, but not the obligation, to initiate legal proceedings to protect the Patent Rights from infringement, with respect to a Claim of a Patent Right in the Field in the Territory, and prosecute infringers at Licensee’s expense. Before
commencing such action, Licensee and, as applicable, any Affiliate, shall consult with BIDMC, concerning the advisability of bringing suit, the selection of counsel and the jurisdiction for such action (provided

  
 7 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
Licensee must have BIDMC’s prior written consent (not to be unreasonably withheld) with respect to selection of jurisdiction for any action in which BIDMC may be joined as a party-plaintiff)
and shall use reasonable efforts to accommodate the views of BIDMC regarding the proposed action, especially but without limitation with respect to potential effects on the public interest. Licensee shall be responsible to BIDMC for all costs,
expenses and liabilities arising out or and in connection with any such action and shall indemnify and hold BIDMC harmless therefrom, regardless of whether BIDMC is a party-plaintiff, except for the expense of any independent counsel retained by
BIDMC in accordance with Section 6.2 below. Licensee shall keep BIDMC informed of the progress of such proceedings and shall make its counsel reasonably available to BIDMC for discussion of such proceedings. BIDMC shall also be entitled to
independent counsel in such proceedings but at its own expense, said expense to be offset against any damages received by the Licensee bringing suit in accordance with Section 6.4 

6.2    BIDMC Right to Prosecute and/or Join as a Party-Plaintiff. 

(a)    In the event that Licensee elects not to take action pursuant to this Section 6.1, Licensee shall so notify
BIDMC promptly in writing of its intention in good time to enable BIDMC to meet any deadlines by which an action must be taken to establish or preserve any enforcement rights and BIDMC shall have the right to take steps to protect the Patent Rights
from infringement, with respect to a Claim of a Patent Right in the Field in the Territory, and prosecute infringers at BIDMC’s expense and subject to any third party rights. If BIDMC notifies Licensee that it intends to so prosecute, subject
to any third party rights, BIDMC shall use reasonable efforts, within [***] of its notice to Licensee, to (i) cause such infringement to terminate; (ii) reach a settlement with infringers; or (iii) initiate legal proceedings against
the infringer. Nothing in this Section 6.2 shall be construed to prevent Licensee from initiating legal proceedings, in accordance with its independent judgement of the merits of an infringement action, as provided in Section 6.1. 

(b)    If Licensee elects to commence an action as described in Section 6.1 above, BIDMC shall have, in its sole
discretion and at its own expense, the option to voluntarily join such action as a party-plaintiff. If required by law for the purposes of Licensee bringing an action against an alleged infringer, BIDMC agrees that it shall allow Licensee to join
BIDMC in such action as a party-plaintiff 
 6.3    Notice of Actions; Settlement. Licensee shall promptly inform
BIDMC of any action or suit relating to Patent Rights and shall not enter into any settlement, consent judgment or other voluntary final disposition of any action relating to Patent Rights, including but not limited to appeals, that would adversely
affect the validity, patentability or enforceability of the Patent Rights without the prior written consent of BIDMC, which shall not be unreasonably withheld or delayed. 

  
 8 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 6.4    Recovery. Subject to any third party rights, any award
paid by third parties as the result of such proceedings (whether by way of settlement or otherwise) shall first be applied to reimbursement of any legal fees and expenses incurred by both Parties, in proportion to their expenditures, and then the
remainder, if any, shall be distributed between the Parties as follows: 
 (a)    Licensee shall receive an amount equal
to its lost profits or a reasonable royalty on the infringing sales, or whichever measure of damages the court shall have applied; and 

(b)    the balance, if any, remaining after Licensee and BIDMC have been compensated under Section 6.4(a) shall be
shared equally by the Parties. 
 7. INDEMNIFICATION AND INSURANCE 

7.1    Indemnification. 

(a)    Licensee shall indemnify, defend and hold harmless BIDMC and its Affiliates and their respective trustees,
directors, officers, medical and professional staff, employees, and agents and their respective successors, heirs and assigns (the “Indemnitees”), against any liability, damage, loss or expense (including reasonable attorney’s fees
and expenses of litigation) incurred by or imposed upon the Indemnitees or any one of them in connection with any claims, suits, actions, demands or judgments commenced or obtained by a third party arising out of any theory of liability, including
without limitation, any theory of product liability (including, but not limited to, actions in the form of contract, tort, warranty, or strict liability) concerning any Product or Process made, used or sold pursuant to any right or license granted
under this Agreement. BIDMC shall promptly provide written notice to Licensee of any claim to which indemnification applies under this Section 7.1(a). 

(b)    Licensee agrees, at its own expense, to, defend against and resolve, and will have the right to assume and control
the defense and resolution of, any actions or claims brought or filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought; provided, however, that any
Indemnitee shall have the right to retain its own counsel, at the expense of Licensee, if representation of such Indemnitee by counsel retained by Licensee would be inappropriate because of actual or potential conflicts of interests of such
Indemnitee and any other party represented by such counsel. Licensee agrees to keep BIDMC informed of the progress in the defense and disposition of such claim and to consult with BIDMC prior to any proposed settlement. The party indemnified
hereunder will reasonably cooperate with Licensee at Licensee’s expense and will make available to Licensee relevant information under the control of such indemnified party. 

(b)    This Section 7.1 shall survive expiration or termination of this Agreement. 

  
 9 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 7.2    Insurance. 

(a)    Beginning at such time as any Product or Process licensed under this Agreement is being commercially distributed,
sold, leased or otherwise transferred, or performed or used (other than for the purpose of obtaining regulatory approvals), by Licensee, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in
amounts not less than $[***] per incident and $[***] annual aggregate and naming the Indemnitees as additional insureds. Such commercial general liability insurance shall provide (i) product liability coverage and (ii) broad form
contractual liability coverage for the indemnification obligations under Section 7.1 of this Agreement. If Licensee or its Affiliates or Sublicensees elects to self-insure all or part of the limits described above (including deductibles or
retentions which are in excess of $[***] annual aggregate), such self-insurance program must be reasonably acceptable to the Licensor, provided that if a Sublicensee elects to self-insure and such Sublicensee has a market capitalization of at least
[***] dollars ($[***]), then such Sublicensee’s self-insurance program shall automatically be deemed reasonably acceptable to Licensor and not subject to Licensor’s review. The minimum amounts of insurance coverage required under this
Section 7.2 shall not be construed to create a limit of liability with respect to the indemnification obligations under Section 7.1 of this Agreement. 

(b)    Licensee shall provide BIDMC with written evidence of such insurance upon request of BIDMC. Licensee shall provide
BIDMC with written notice at least [***] prior to the cancellation, non-renewal or material change in such insurance; if Licensee does not obtain replacement insurance providing comparable coverage prior to
the expiration of such [***] period, BIDMC shall have the right to terminate this Agreement pursuant to Section 9.3 (and subject to the cure right therein). 

(c)    Licensee shall maintain such commercial general liability insurance beyond the expiration or termination of this
Agreement during (i) the period that any such Product or Process, is being commercially distributed, sold, leased or otherwise transferred, or performed or used (other than for the purpose of obtaining regulatory approvals), by Licensee or by a
licensee, affiliate or agent of Licensee and (ii) a reasonable period after the period referred to in (c) (i) above which in no event shall be less than [***]. 

(d)    This Section 7.2 shall survive expiration of termination of this Agreement. 

7.3    Affiliates and Sublicensees. Licensee shall require all its Affiliates and Sublicensees (other than Third
Party Contractors) to comply with the provisions and obligations under this Section 7 as if such entity were the Licensee. 

  
 10 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 8. REPRESENTATION; DISCLAIMER OF WARRANTIES; LIMITATION OF LIABILITY 

8.1    Representation. To the best knowledge of BIDMC’s Technology Ventures Office, BIDMC represents that:

 (a)    No approval, authorization, consent or other order or action of or filing with any court, administrative agency
or other governmental authority is required for the execution and delivery by it of this Agreement or the consummation by it of the transactions contemplated hereby; 

(b)    it has full right and authority to enter into this Agreement and to grant the licenses and other rights to Licensee
as herein described; 
 (c)    the execution, delivery and performance of this Agreement does not conflict with any other
agreement, contract, instrument or understanding, oral or written, to which BIDMC is a party, or by which it is bound; and 

(d)    none of BIDMC nor any of its Affiliates has entered into any agreement or otherwise licensed, granted, assigned,
transferred, conveyed or otherwise encumbered or disposed of any right, title or interest in or to any of the Patent Rights that would conflict with or impair the scope of any rights or licenses granted hereunder. 

8.2    No Warranties. BIDMC HEREBY DISCLAIMS AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR
IMPLIED, CONCERNING THE PATENT RIGHTS AND ANY OF THE RIGHTS GRANTED HEREUNDER, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF PATENT RIGHTS CLAIMS, WHETHER ISSUED OR
PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. SPECIFICALLY, AND NOT TO LIMIT THE FOREGOING, BIDMC MAKES NO WARRANTY OR REPRESENTATION (i) REGARDING THE VALIDITY OR SCOPE OF ANY OF THE CLAIM(S), WHETHER ISSUED
OR PENDING, OF ANY OF THE PATENT RIGHTS, AND (ii) THAT THE EXPLOITATION OF THE PATENT RIGHTS OR ANY PRODUCT OR PROCESS WILL NOT INFRINGE ANY PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF BIDMC OR OF ANY THIRD PARTY. 

8.3    Limitation of Liability. IN NO EVENT SHALL BIDMC OR ANY OF ITS AFFILIATES OR ANY OF THEIR RESPECTIVE
TRUSTEES, DIRECTORS, OFFICERS, MEDICAL AND PROFESSIONAL STAFF, EMPLOYEES AND AGENTS BE LIABLE TO LICENSEE OR ANY OF ITS AFFILIATES, SUBLICENSEES OR DISTRIBUTORS FOR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND ARISING IN ANY
WAY OUT OF THIS AGREEMENT 

  
 11 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
OR THE LICENSE RIGHTS GRANTED HEREUNDER, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, INCLUDING WITHOUT LIMITATION ECONOMIC DAMAGES OR INJURY TO PROPERTY OR LOST PROFITS, REGARDLESS OF WHETHER
BIDMC SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING. 
 9. TERMINATION

 9.1    Termination for Failure to Pay. If Licensee fails to make any payment due hereunder, BIDMC shall
have the right to terminate this Agreement upon fifteen (15) business days written notice, unless Licensee makes such payments plus any interest due, as set forth in Section 3.3, within said fifteen (15) day notice period. If payments
are not made, BIDMC may immediately terminate this Agreement at the end of said fifteen (15) business day period. 

9.2    Termination for Insolvency. BIDMC may terminate this Agreement immediately upon written notice with no
further notice obligation or opportunity to cure if Licensee shall become insolvent, shall make an assignment for the benefit of creditors, or shall have a petition in bankruptcy filed for or against it that is not dismissed within sixty
(60) days of filing. 
 9.3    Termination for Non-Financial Default.
If Licensee or any of its Affiliates shall materially default in the performance of any of its material obligations under this Agreement (including any such obligations undertaken by Sublicensees) (excluding as provided for in Sections 9.1 and 9.2)
and if such material default has not been cured within sixty (60) days after notice by BIDMC in writing of such material default, then at the end of such cure period, BIDMC may, at its option, in its sole discretion, either (i) immediately
terminate any licenses granted hereunder with respect to the country or countries in which such material default has occurred, or (ii) terminate the Agreement in its entirety. BIDMC shall have the foregoing termination rights immediately, upon
written notice, if any such same material default occurs more than three times, even if cured within such sixty (60) day periods. 

9.4    Patent Challenge. During the Term, if a Sublicensee (excluding a Third Party Contractor) brings a Patent
Challenge or assists another party in bringing a Patent Challenge (except as required under a court order or subpoena or except as raised as a defense against a claim, action or proceeding asserted by BIDMC or its Affiliates against such
Sublicensee), then BIDMC may send a written demand to Licensee to terminate such sublicense. If Licensee fails to so terminate such sublicense within sixty (60) days after BIDMC’ s demand, BIDMC may immediately terminate this Agreement
and/or any licenses granted hereunder. 
 9.5    Termination by Licensee. Licensee shall have the right to
terminate this Agreement for any reason by giving ninety (90) days advance written notice to BIDMC. 

  
 12 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 9.6    Effects of Termination of Agreement. 

(a)    General. Upon termination of this Agreement or any of the licenses hereunder for any reason, final reports in
accordance with Section 5.1 shall be submitted to BIDMC and all payments, including without limitation any unreimbursed Patent Costs, accrued or due to BIDMC as of the termination date shall become immediately payable. The termination or
expiration of this Agreement or any licenses granted hereunder shall not relieve any Party or its Affiliates of obligations arising before such termination or expiration. For the avoidance of doubt, termination of this Agreement shall not affect the
right of Licensee, its Affiliates, Sublicensees and Distributors to continue operating under Licensee’s rights as joint owner and co-applicant of the Patent Rights. 

(b)    Survival. The following provisions shall survive the expiration or termination of this Agreement: Sections 1,
2.2 (last two sentences of the first paragraph), 3, 7, 8, 11 and 9.6 and Appendix B. 
 10. COMPLIANCE WITH LAW 

10.1    Compliance. Licensee shall have the sole responsibility for compliance with all government statutes and
regulations that relate to Products and Processes, including, but not limited to, those of the Food and Drug Administration and the Export Administration, and any applicable laws and regulations of any other country in the Territory. Licensee agrees
that it shall be solely responsible for obtaining any necessary licenses to export, re¬export, or import Products or Processes covered by Patent Rights and/or Confidential Information and that it will indemnify, defend, and hold BIDMC harmless
(in accordance with Section 8.1) for the consequences of any violation by Licensee, its Affiliates, Sublicensees or Distributors of any such laws or regulations. 

10.2    Patent Numbers. Licensee shall cause all Products sold in the United States to be marked with all applicable
U.S. Patent Numbers, to the full extent required by United States law. Licensee shall similarly cause all Products shipped to or sold in any other country to be marked in such a manner as to conform with the patent laws and practices of such
country. 
 11. ASSIGNMENT 

11.1    Assignment. This Agreement is personal to Licensee and no rights or obligations may be assigned by Licensee
without the prior written consent of BIDMC, except that Licensee may assign its rights and obligations under this Agreement to an Affiliate or to a successor in connection with the merger, consolidation, or sale of all or substantially all of its
assets or equity or that portion of its business to which this Agreement relates (“Assignment”); provided, however, that Licensee shall provide notification to BIDMC within [***] of such Assignment 

  
 13 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 12. MISCELLANEOUS 

12.1    Entire Agreement. This Agreement and the Sponsored Research Agreement (BIDMC Agreement No. A8755) and its
Amendment No. 1 (BIDMC Agreement No. A8755) between the Parties, dated January 1, 2015 and February 2, 2016 respectively with continuing obligations, non-disclosure agreement constitutes the
entire understanding between the Parties with respect to the subject matter hereof. 
 12.2    Notices. Any
notice, communication or payment required or permitted to be given or made hereunder shall be in writing and, except as otherwise expressly provided in this Agreement, shall be deemed given or made and effective (i) when delivered personally;
or (ii) when delivered by telex or telecopy (if not a payment); or (iii) when received if sent by overnight express or mailed by certified, registered or regular mail, postage prepaid, addressed to parties at their address stated below, or
to such other address as such party may designate by written notice in accordance with the provisions of this Section 10.2. 
  

	BIDMC:	 Attn: [***] 

Beth Israel Deaconess Medical Center 

330 Brookline Avenue, BR2 

Boston, MA 02215 

Phone: 617 667-9490 

Fax: 617-667-4445 

Email: [***] 
  

	With a copy to:	 General Counsel 

Legal Department 

Beth Israel Deaconess Medical Center 

330 Brookline Avenue, Suite 300 

Boston, MA 02215 
  

	LICENSEE:	 Attn: John Celebi 

Chief Operating Officer 

X4 Pharmaceuticals, Inc. 

784 Massachusetts Avenue, Suite 140 

Cambridge MA 02139 

12.3    Amendment; Waiver. This Agreement may be amended and any of its terms or conditions may be waived only by a
written instrument executed by an authorized signatory of the Parties or, in the case of a waiver, by the Party waiving compliance. The failure of either Party at any time or rimes to require performance of any provision hereof shall in no manner
affect its rights at a later time to enforce the same. No waiver by either Party of any condition or term shall be deemed as a further or continuing waiver of such condition or term or of any other condition or term. 

  
 14 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 12.4    Binding Effect. This Agreement shall be binding upon and
inure to the benefit of and be enforceable by the Parties hereto and their respective permitted successors and assigns. 

12.5    Force Majeure. Neither Party shall be responsible for delays resulting from fire, explosion, flood, war,
sabotage, strike or riot, or similar causes beyond the reasonable control of such Party, provided that the nonperforming Party uses commercially reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this
Agreement with reasonable dispatch whenever such causes are removed. 
 12.6    Use of Name. Neither Party shall
use the name of the other Party or of any trustee, director, officer, staff member, employee, student or agent of the other Party or any adaptation thereof in any advertising, promotional or sales literature, publicity or in any document employed to
obtain funds or financing without the prior written approval of the Party or individual whose name is to be used. 

12.7    Governing Law. This Agreement shall be governed by and construed and interpreted in accordance with the laws
of the Commonwealth of Massachusetts, excluding with respect to conflict of laws, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted.
Each Party agrees to submit to the exclusive jurisdiction of the Superior Court for Suffolk County, Massachusetts, and the United States District Court for the District of Massachusetts with respect to any claim, suit or action in law or equity
arising in any way out of this Agreement or the subject matter hereof. 
 12.8    BIDMC Policies. Licensee
acknowledges that BIDMC’s employees and medical and professional staff members and the employees and staff members of BIDMC’s Affiliates are subject to the applicable policies of BIDMC and such Affiliates, including, without limitation,
policies regarding conflicts of interest, intellectual property and other matters. Licensee shall provide BIDMC with any agreement it proposes to enter into with any employee or staff member of BIDMC or any of BIDMC’s Affiliates for
BIDMC’s prior review and shall not enter into any oral or written agreement with such employee or staff member which it knows conflicts with any such policy. BIDMC shall provide Licensee, at Licensee’s request, with copies of any such
policies applicable to any such employee or staff member. 
 12.9    Severability. If any provision(s) of this
Agreement are or become invalid, are ruled illegal by any court of competent jurisdiction or are deemed unenforceable under then current applicable law from time to time in effect during the term hereof; it is the intention of the parties that the
remainder of this agreement shall not be effected thereby. It is further the intention of the parties that in lieu of each such provision which is invalid, illegal or unenforceable, there be substituted or added as part of this Agreement a provision
which shall be as similar as possible in economic and business objectives as intended by the parties to such invalid, illegal or enforceable provision, but shall be valid, legal and enforceable. 

  
 15 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 12.10    Interpretation. The parties hereto are sophisticated,
have had the opportunity to consult legal counsel with respect to this transaction and hereby waive any presumptions of any statutory or common law rule relating to the interpretation of contracts against the drafter. 

12.11    Headings. All headings are for convenience only and shall not affect the meaning of any provision of this
Agreement. 
 [Remainder of page intentionally left blank] 

  
 16 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives as of the date first written above. 
 The Effective Date of this License Agreement is December 23,
2016. 
  

													
	X4 PHARMACEUTICALS, INC.	 	BETH ISRAEL DEACONESS MEDICAL CENTER
					
	BY:	 	/s/ John Celebi	 		 	BY:	 	/s/ Vikas Sukhatme, M.D., Sc. D.
		 	  Name:	 	John Celebi	 		 		 	  Name:	 	Vikas Sukhatme, M.D., Sc. D.
					
	TITLE:	 	Chief Operating Officer	 		 	TITLE:	 	Chief Academic Officer
					
	DATE:	 	12/29/2016	 		 	DATE:	 	12/27/2016

  
 17 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Appendix A 

[***] 

  
 18 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Appendix B 

CONFIDENTIALITY TERMS AND CONDITIONS 

1.    Definition of Confidential Information. “Confidential Information” shall mean any information,
including but not limited to data, techniques, protocols or results, or business, financial, commercial or technical information, disclosed by one Party (each a “Discloser” as applicable) to the other Party (each a “Recipient” as
applicable) in connection with the terms of that certain Exclusive License Agreement dated December , 2016 (the “License Agreement”) and identified as confidential at the time of disclosure. Capitalized terms used in this Appendix that are
not otherwise defined herein have the meanings ascribed in the License Agreement to which this Appendix is attached and made a part thereof. 

2.    Exclusions. “Confidential Information” under this Agreement shall not include any information that
(i) is or becomes publicly available through no wrongful act of Recipient; (ii) was known by Recipient prior to disclosure by Discloser, as evidenced by tangible records; (iii) becomes known to Recipient after disclosure from a third
party having an apparent bona fide right to disclose it without any confidentiality obligation; (iv) is independently developed or discovered by Recipient without use of Discloser’s Confidential Information, as evidenced by tangible
records; or (v) is disclosed to another party by Discloser without restriction on further disclosure. The obligations of confidentiality and non-use set forth in this Agreement shall not apply with
respect to any information that Recipient is required to disclose or produce pursuant to applicable law, court order or other valid legal process provided that Recipient promptly notifies Discloser prior to such required disclosure, discloses such
information only to the extent so required and cooperates reasonably with Discloser’s efforts to contest or limit the scope of such disclosure. 

3.    Permitted Purpose. Recipient shall have the right to, and agrees that it will, use Discloser’s
Confidential Information solely for the performance of its obligations and exercise of its rights under the License Agreement (the “Purpose”), except as may be otherwise specified in a separate definitive written agreement negotiated and
executed between the parties. 
 4.    Restrictions. For the term of the License Agreement and a period of [***]
thereafter (and indefinitely with respect to any individually identifiable health information disclosed by BIDMC to Licensee, if any), each Recipient agrees that: (i) it will not use such Confidential Information for any purpose other than as
specified herein; and (ii) it will use reasonable efforts (but no less than the efforts used to protect its own confidential and/or proprietary information of a similar nature) not to disclose such Confidential Information to any other person
or entity except as expressly permitted hereunder or the License Agreement. Recipient may, however, disclose Discloser’s Confidential Information only on a
need-to-know basis to its and its Affiliates employees, staff members and agents (“Receiving Individuals”) who are directly participating in the Purpose and
who are informed of the confidential nature of such information, provided Recipient shall be responsible for compliance by Receiving Individuals with the terms of this Agreement and any breach thereof Each party further agrees not to use the name of
the other party or any of its Affiliates or any of their respective trustees, directors, officers, staff members, 

  
 19 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
employees, students or agents in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or financing without the prior written approval of the
party or individual whose name is to be used, in the case of BIDMC such approval to be given by the Public Affairs Department. This Section 4 shall survive termination or expiration of this Agreement. 

5.    Right to Disclose. Discloser represents that to the best of its knowledge it has the right to disclose to each
Recipient all of Discloser’s Confidential Information that will be disclosed hereunder. 
 6.    Ownership.
All Confidential Information disclosed pursuant to this Agreement, including without limitation all written and tangible forms thereof, shall be and remain the property of the Discloser. Upon termination of this Agreement, if requested by Discloser,
Recipient shall return or destroy at Discloser’s discretion all of Discloser’s Confidential Information, provided that Recipient shall be entitled to keep one copy of such Confidential Information in a secure location solely for the
purpose of determining Recipient’s legal obligations hereunder. 
 7.    No License. Nothing in this
Agreement shall be construed as granting or conferring, expressly or impliedly, any rights by license or otherwise, under any patent, copyright, or other intellectual property rights owned or controlled by Discloser relating to Confidential
Information, except as specifically set forth in the License Agreement. 
 8.    Remedies. Each party acknowledges
that any breach of this Agreement by it may cause irreparable harm to the other party and that each party is entitled to seek injunctive relief and any other remedy available at law or in equity. 

9.    Export Restrictions. The Confidential Information is subject to the export and customs laws and regulations of
the United States and any other applicable country and neither party will export, re-export or transship, directly or indirectly, such information to any country without first obtaining proper governmental
approval, as necessary. Licensee will not disclose any export controlled information to BIDMC without the express prior written consent of BIDMC Technology Ventures Office. Licensee will indemnify BIDMC for any and all claims, actions, damages or
liabilities of any kind related to Company’s failure to comply with this section. 
 10.    General. These
Confidentiality Terms and Conditions, along with the License Agreement, contain the entire understanding of the parties with respect to the subject matter hereof, and supersede any prior oral or written understandings between the parties relating to
confidential treatment of information. Sections 1, 2, 4, 7, 10 and 11 of these Confidentiality Terms and Conditions shall survive any expiration or termination of the License Agreement. 

  
 20 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]